<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00299000 on 2006_11_14: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00299000">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00299000">&#8593; Current version of this study</a></div><h1>View of NCT00299000 on
  2006_11_14</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00299000</td>
</tr>
<tr>
<th>Updated:</th><td>2006_11_14</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>A Phase 4 Multi-Center, Multi-National, Open-Label, Randomized, Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With Maroteaux-Lamy Syndrome (MPS VI)</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>The purpose of the study is to evaluate the safety and efficacy of two dose levels of Naglazyme in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>The primary objective of the study is to evaluate the efficacy of two dose levels of Naglazyme in preventing the progression of skeletal dysplasia in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.<br>The secondary objective of the study is to evaluate the efficacy of the two dose levels of Naglazyme in preventing several measures of disease progression in infants under the age of one year who have MPS VI by monitoring urinary GAGs, gross and fine motor function, cardiac function, vision, hearing, and use of health resources.<br>The safety objective of the study is to evaluate the safety of two dose levels of Naglazyme in infants under the age of one year who have MPS VI.</p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 4</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Prevention</td>
</tr>
<tr>
<th>Study design</th><td>Randomized</td>
</tr>
<tr>
<th>Study design</th><td>Open Label</td>
</tr>
<tr>
<th>Study design</th><td>Dose Comparison</td>
</tr>
<tr>
<th>Study design</th><td>Parallel Assignment</td>
</tr>
<tr>
<th>Study design</th><td>Safety/Efficacy Study</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: 
         The primary objective of the study is to evaluate the efficacy of two dose levels of Naglazyme in preventing the progression of skeletal dysplasia in infants under the age of one year who have MPS VI
      </td>
</tr>
<tr>
<th>Condition</th><td>
         Mucopolysaccharidosis VI
      </td>
</tr>
<tr>
<th>Condition</th><td>
         Maroteaux-Lamy Syndrome
      </td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: galsulfase</div>
</td>
</tr>
<tr>
<th>URL</th><td>http://www.BRMN.com</td>
</tr>
<tr>
<th>See also</th><td>
<p>BioMarin Pharmaceutical Inc Website</p>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>Recruiting</td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Inclusion Criteria:<br> &nbsp;- Signed informed consent by a parent or legal guardian after the nature of the study has been explained and prior to any research-related procedures<br>
<br> &nbsp;- Willing and able to comply with all study procedures<br>
<br> &nbsp;- Equal to or greater than 36 weeks estimated gestational age by physical exam at birth<br>
<br> &nbsp;- Has a diagnosis of MPS VI based on a documented prenatal diagnosis or fibroblast or leukocyte N-acetylgalactosamine 4-sulfatase (ASB) enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory<br>
<br> &nbsp;- Is less than one year of age<br>
<br> &nbsp;- Has no evidence of skeletal dysplasia based on physical exam<br>
<br>
<br>
<br>Exclusion Criteria:<br> &nbsp;- Perceived to be unreliable or unavailable for study participation or, if under the age of 18, have parents or legal guardians who are perceived to be unreliable or unavailable<br>
<br> &nbsp;- Use of any investigational drug within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments<br>
<br> &nbsp;- Concurrent disease or condition that would interfere with study participation or safety (i.e., has previously undergone hematopoietic stem cell transplantation such as bone marrow or cord blood transplantation, or major organ transplantation)<br>
<br> &nbsp;- Any condition that, in the view of the PI, renders the subject at high risk from treatment compliance and/or completing the study<br>
<br> &nbsp;- Has known hypersensitivity to Naglazyme<br>
<br> &nbsp;- Has previously received Naglazyme</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Both
         </td>
</tr>
<tr>
<th>Maximum age</th><td>1 Years</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th>Expected enrollment</th><td>4</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>BioMarin Pharmaceutical</td>
</tr>
<tr>
<th>Organization study ID</th><td>ASB-008</td>
</tr>
<tr>
<th>Sponsor</th><td>
               BioMarin Pharmaceutical
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United States: Food and Drug Administration
         </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
